ABSTRACT
Nivolumab is anti-programmed death 1 (PD1) receptor antibody, which can be used in the treatment of metastatic squamous cell cancer. By blocking the PD1 receptors on T cells, it enhances T-cell response against cancer cells. A 69-year-old man, who works as a farmer, presented with erythematous lichenified plaques on sun-exposed areas, such as the face, the chest, and both the forearms. Before the hospital visit, he was receiving lung cancer treatment with paclitaxel and cisplatin, but there was no improvement. Subsequently, the regimen was changed into nivolumab, and PET-CT showed decreased in cancer size. However, skin rashes developed simultaneously. It is consistent with the results of a previous study in which cutaneous side effects developed in 42% of responders compared to 7% of non-responders. Herein, we report a case of nivolumab-induced cutaneous toxicity on sun-exposed areas based on the clinical findings, including the distribution of rashes, which were improved after decreasing the nivolumab dose with literature review.
Subject(s)
Aged , Humans , Cisplatin , Exanthema , Farmers , Forearm , Lung Neoplasms , Neoplasms, Squamous Cell , Paclitaxel , Programmed Cell Death 1 Receptor , T-Lymphocytes , ThoraxABSTRACT
Los inhibidores del receptor de factor de crecimiento epidérmico son un grupo de drogas nuevas usadas para el tratamiento de tumores en estadios avanzados. Estas drogas producen conmucha frecuencia toxicidad cutánea. El objetivo de este artículo es realizar una revisión de estas reacciones cutáneas y el manejo de las mismas.
Epidermal growth factor - receptor inhibitors constitute a new group of drugs used for the treatment of malignant tumors in advanced stages. These drugs produce with high frequency cutaneous toxicity. The aim of this paper is to review those cutaneous reactions, and their management.
Subject(s)
Humans , ErbB Receptors/antagonists & inhibitors , Antineoplastic Agents/adverse effects , Acneiform Eruptions/etiology , Drug Eruptions/etiology , Skin/pathologyABSTRACT
Chemotherapeutic agents may induce cutaneous toxicity. Although the cutaneous side effects of chemotherapeutic agents are rarely life threatening, they can impact the physical, psychological, and social well-being of patients receiving these therapies. Recently, a number of new anti-cancer agents have been approved for the treatment of cancer. These new anti-cancer agents manifest a variety of cutaneous reactions. This article reviews the cutaneous toxicity of these agents, particularly those which dermatologists are likely to be consulted about.
ABSTRACT
OBJECTIVE: To study the cutaneous toxicity of Compound p-cymene cream.METHODS: Different dosage of Compound p-cymene cream was applied on normal skin and the damaged skin of hairless area of rabbits,and the presence of acute toxicity.RESULTS: Compound p-cymene cream induced neither acute toxicity nor cutaneous irritant reaction.CONCLUSION: Compound p-cymene cream is a safe locally applied external preparation.